Neuberger Berman Group
APGE

Neuberger Berman Group’s Apogee Therapeutics APGE Stock Holding History

Neuberger Berman Group’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Buy
+2,301
New +$207K ﹤0.01% 1997
2026
Q1 		– Sell
-99,648
Closed -$7.52M – 2167
2025
Q4 		$7.52M Buy
+99,648
New +$6.28M 0.01% 873

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Neuberger Berman Group's APGE Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 2,301 shares worth $305K. The stake represents ﹤0.01% of the portfolio and ranks #1997 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in APGE as recently as Q4 2025.

Neuberger Berman Group first reported a position in APGE in Q4 2025 and has held it in 2 quarters since. The position peaked at $7.52M in Q4 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Neuberger Berman Group held 2,301 shares of Apogee Therapeutics worth $305K as of Q2 2026.
  • Apogee Therapeutics was a new Neuberger Berman Group position in Q2 2026.
  • Apogee Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #1997 holding.
  • Neuberger Berman Group first reported a position in Apogee Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Neuberger Berman Group's Apogee Therapeutics position peaked at $7.52M in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.